Zealand Pharma A/S
ZLDPF
$62.50
-$0.79-1.25%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -81.87% | -77.78% | 317.54% | 235.77% | 241.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -81.87% | -77.78% | 317.54% | 235.77% | 241.29% |
| Cost of Revenue | -33.72% | 44,632.26% | 690.76% | -- | -92.79% |
| Gross Profit | -83.55% | -83.30% | 261.21% | 219.98% | 773.99% |
| SG&A Expenses | 86.58% | 53.44% | 27.56% | 4.13% | -15.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 101.14% | 137.93% | 78.96% | 78.96% | -- |
| Total Operating Expenses | 47.10% | 33.28% | 29.95% | 15.83% | -0.31% |
| Operating Income | -126.46% | -102.72% | 4.04% | 14.16% | 30.56% |
| Income Before Tax | -52.90% | -39.77% | 26.74% | 28.79% | 25.62% |
| Income Tax Expenses | 9.81% | 21.96% | 27.23% | 31.11% | 18.75% |
| Earnings from Continuing Operations | -53.35% | -40.25% | 26.74% | 28.77% | 25.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.35% | -36.07% | 28.21% | 35.56% | 40.83% |
| EBIT | -126.46% | -102.72% | 4.04% | 14.16% | 30.56% |
| EBITDA | -188.85% | -159.58% | -37.90% | -23.96% | 33.15% |
| EPS Basic | -29.92% | -14.20% | 38.64% | 48.49% | 51.70% |
| Normalized Basic EPS | -110.45% | -70.45% | 6.66% | 27.14% | 43.41% |
| EPS Diluted | -29.50% | -13.88% | 38.42% | 48.33% | 51.54% |
| Normalized Diluted EPS | -109.63% | -69.92% | 6.43% | 26.94% | 43.19% |
| Average Basic Shares Outstanding | 17.40% | 18.29% | 19.34% | 25.68% | 25.85% |
| Average Diluted Shares Outstanding | 16.42% | 17.26% | 20.28% | 26.69% | 26.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
